Marker Therapeutics, Inc. (NASDAQ:MRKR) Short Interest Update

Marker Therapeutics, Inc. (NASDAQ:MRKR) saw a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 83,600 shares, an increase of 66.9% from the November 30th total of 50,100 shares. Based on an average daily volume of 55,200 shares, the short-interest ratio is presently 1.5 days. Approximately 1.3% of the shares of the company are sold short.

Insider Activity at Marker Therapeutics

In other Marker Therapeutics news, major shareholder Enterprise Associates 16 New purchased 554,250 shares of Marker Therapeutics stock in a transaction dated Monday, December 23rd. The stock was purchased at an average price of $3.20 per share, with a total value of $1,773,600.00. Following the transaction, the insider now directly owns 1,625,678 shares of the company’s stock, valued at $5,202,169.60. This trade represents a 51.73 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Steve Elms acquired 11,085 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The stock was acquired at an average cost of $3.20 per share, for a total transaction of $35,472.00. Following the acquisition, the director now owns 325,370 shares of the company’s stock, valued at $1,041,184. The trade was a 3.53 % increase in their position. The disclosure for this purchase can be found here. 17.35% of the stock is owned by insiders.

Institutional Investors Weigh In On Marker Therapeutics

An institutional investor recently raised its position in Marker Therapeutics stock. Wedbush Securities Inc. lifted its position in Marker Therapeutics, Inc. (NASDAQ:MRKR) by 52.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 69,500 shares of the company’s stock after purchasing an additional 24,000 shares during the period. Wedbush Securities Inc. owned about 0.78% of Marker Therapeutics worth $377,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 22.39% of the company’s stock.

Wall Street Analyst Weigh In

Separately, LADENBURG THALM/SH SH lifted their price target on shares of Marker Therapeutics from $11.00 to $19.00 and gave the stock a “buy” rating in a research note on Monday, October 21st.

Marker Therapeutics Stock Performance

MRKR traded up $0.12 during midday trading on Friday, reaching $3.49. The company had a trading volume of 78,461 shares, compared to its average volume of 31,547. The business has a 50-day moving average of $3.72 and a two-hundred day moving average of $3.83. Marker Therapeutics has a 1 year low of $2.44 and a 1 year high of $6.16.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.